Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Similar Items

• Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
  od: Das, Ishani, i dr.
  Izdano: (2019)
• Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
  od: Azimi, Alireza, i dr.
  Izdano: (2017)
• Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
  od: Platz, Anton, i dr.
  Izdano: (2007)
• PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
  od: Vidarsdottir, Linda, i dr.
  Izdano: (2021)
• Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
  od: Das, Ishani, i dr.
  Izdano: (2020)